With the approval, Evita joins GenBioPro as the two generic manufacturers of mifepristone indicated for the medical termination of intrauterine pregnancy through 70 days of gestation. The quiet FDA approval comes at a time when future access to abortion drugs in the US is under considerable political tampering. They added that the FDA’s past decisions to suspend certain restrictions on mifepristone access had not been given “adequate consideration” at the time. If the FDA were to implement mifepristone restrictions, it would further reduce abortion access in a post-Roe versus Wade America. Politicised response to scientific evidenceThe approval of a second mifepristone generic was met with a divisive reaction.